Lung cancer is the leading cause of cancer mortality across the globe, claiming more lives than colon, breast and prostate cancers—combined. At the 2018 BIO International Convention, Johnson & Johnson Innovation and Boston University announced a five-year alliance aimed at fundamentally changing the way lung cancer is detected and treated—with the hope of changing those grim statistics. As part of the new alliance, Johnson & Johnson Innovation will fund a Lung Cancer Center at Boston University Medical Center that will be helmed by Avrum Spira, M.D., Professor of Medicine, Pathology and Bioinformatics, Boston University, and Global Head, the Lung Cancer Initiative at Johnson & Johnson.
This article first appeared on jnj.com. Click here to read the rest of this article.